Concerns over potential side effects of AstraZeneca PLC’s COVID-19 vaccine failed to dent the trading debut of its South Korean partner, SK Bioscience Co, which yesterday finished its first day of trading with a 160 percent gain, boosting its market capitalization to 12.9 trillion won (US$11.5 billion).
Following a record number of bids from retail investors for its US$1.33 billion initial public offering (IPO), shares of SK Bioscience soared by their daily limit to 169,000 won from the float price of 65,000 won.
The heavily subscribed IPO by SK Bioscience, the local manufacturer of AstraZeneca’s vaccine, is the largest domestic listing since game developer Netmarble Corp raised US$2.39 billion in 2017.
Photo: Bloomberg
It comes just a week after a hot US$4.6 billion New York share sale by e-commerce giant Coupang Inc drew attention to South Korean listings globally.
SK Bioscience’s debut comes as several EU countries, such as Germany and France, temporarily suspend the AstraZeneca vaccine rollout on worries about side effects.
While the WHO has said that the vaccine should continue to be administered, the European Medicines Agency was to provide a definitive assessment yesterday.
“It is difficult to tell exactly how much negative impact this will have on SK Bioscience,” analyst Douglas Kim said in a note on investment research network Smartkarma before its trading debut.
South Korea plans to inoculate 12 million people before July, with early batches of the vaccine relying mostly on AstraZeneca shots manufactured in SK Bioscience’s factory in Andong, South Korea.
SK Bioscience last month signed a licensing agreement with Novavax Inc to manufacture its COVID-19 vaccine in South Korea.
SK Bioscience is among numerous South Korean companies trying to ride the boom market after the country’s benchmark KOSPI soared 30 percent last year on a flood of retail buying.
Drugmakers and healthcare stocks were among the biggest winners since the start of the COVID-19 pandemic, although their stock price gains have lost steam this year.
SK Bioscience benefited from retail investors’ hunger for shares. South Korean mom-and-pop buyers poured in a record 63.6 trillion won to get their hands on SK Bioscience shares, beating the previous 59 trillion won in retail bids for last year’s US$321.5 million IPO by Kakao Games Corp, the gaming unit of South Korea’s leading messaging app, Kakao Corp.
Institutional investors, who made up 55 percent of the SK Bioscience IPO, also poured into the offering. Bids from institutional investors were oversubscribed by 1,275 times.
SK Bioscience has said that it is planning to use the IPO proceeds for research and development, as well as the construction of a plant to produce the next-generation pneumococcal vaccine in its pipeline, among other things.
Chinese technology giants including Huawei Technologies Co (華為) and Baidu Inc (百度) as well as start-ups are stockpiling high bandwidth memory (HBM) semiconductors from Samsung Electronics Co in anticipation of US curbs on exports of the chips to China, three sources said. The companies have ramped up their buying of the artificial intelligence (AI) capable semiconductors since early this year, helping China account for about 30 percent of Samsung’s HBM chip revenue in the first half of this year, one of the sources said. US authorities are planning to unveil an export-control package this month that would impose new restrictions on shipments
‘WORLD’S CHIP GATEKEEPER’: Advocacy groups urged the US justice department to investigate Nvidia, saying it had ‘bullied its way into a prominent investment position’ Antitrust tensions are heating up in the chipmaking industry, as rivals have accused Wall Street darling Nvidia Corp of abusing its market dominance in selling chips that power artificial intelligence (AI) — and the US Department of Justice is now investigating these complaints, technology news site The Information reported. The news outlet, which cited unnamed sources familiar with the discussions, said that justice department officials are looking into concerns that Nvidia is potentially cornering the market and pressuring its customers to unfairly retain business. That includes allegations of Nvidia threatening to punish those who buy products from the Santa Clara, California-based tech
HYPE VERSUS REALITY: Amazon and Microsoft shares slid after their earnings reports because of fears that their big AI investments are not paying off for them After a jam-packed week of earnings reports from megacap technology companies, one thing is clear: As profits slow, investors are not impressed by artificial intelligence (AI) promises anymore. They want to see results. With six companies inside a group known as the “Magnificent Seven” already having reported, year-on-year earnings growth has slowed to nearly 30 percent in the second quarter, down from 50 percent in the previous period. Analysts said they expect that rate to decelerate further, to about 17 percent for those companies in the third quarter. Results from Microsoft Corp, Meta Platforms Inc, Amazon.com Inc and Apple Inc last week signaled
Hong Kong carrier Cathay Pacific Airways Ltd (國泰航空) yesterday said that it would buy at least 30 Airbus SE A330-900 aircraft in a deal valued at US$11 billion as it looks to build on a post-COVID-19 recovery and reach pre-pandemic passenger numbers next year. The firm made the announcement as it reported a drop in profit in the first half of the year, having moved into the black for the first time in four years last year thanks to a pickup in post-pandemic demand. Cathay did not disclose the total price of the planes, but said it had received “significant price concessions”